Comparision of simulect and thymoglobulin induction in an early steroid cessation protocol in renal transplant recipients.

被引：0
|
作者：
Peddi, V. Ram [1 ]
Ueda, Kimi [1 ]
Bry, William [1 ]
Bohannon, Lawrence [1 ]
Silkensen, John [1 ]
Warvarix, Vasyl [1 ]
Tsien, Isabelle [1 ]
Walsh, Brian [1 ]
Arsalane, Paul [1 ]
Katznelson, Steven [1 ]
机构：
[1] Calif Pacific Med Ctr, Geraldine Brush Canc Res Inst, San Francisco, CA 94115 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2007年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
1190
引用
收藏
页码：453 / 453
页数：1
相关论文
共 50 条
  • [21] Steroid sparing regimens and monoclonal antibody induction reduces the incidence of infection in renal transplant recipients.
    Chan, Kakit
    Charif, Rawya
    Galliford, Jack
    Cairns, Tom
    Duncan, Neill
    Hakim, Nadey
    McLean, Adam
    Palmer, Andrew
    Papalois, Vassilios
    Taube, David
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 364 - 364
  • [22] Tacrolimus nephrotoxicity as a result of steroid withdrawal in renal transplant recipients.
    Smith, LD
    Allard, JA
    Corbett, J
    Nelson, E
    Shihab, F
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 159 - 160
  • [23] Steroid withdrawal from a sirolimuscyclosporine regimen in renal transplant recipients.
    Mahalati, K
    Kahan, BD
    [J]. TRANSPLANTATION, 2000, 69 (08) : S223 - S223
  • [24] Impact of Steroid Withdrawal on the Immune Response of Renal Transplant Recipients.
    Weimer, Rolf
    Deisz, Sabine
    Dietrich, Hartmut
    Renner, Fabrice
    Suesal, Caner
    Kamali-Ernst, Shirin
    Ernst, Wolfgang
    Padberg, Winfried
    Opelz, Gerhard
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 342 - 342
  • [25] Alemtuzumab vs Thymoglobulin Induction in Highly Sensitized, Kidney Re-Transplant Recipients.
    Shaffer, David
    Truscott, Christy L.
    Tseng, Christine Y.
    Schaefer, Heidi M.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 677 - 677
  • [26] Basiliximab (Simulect®) is safe and effective in combination with triple therapy of Neoral®, steroids and CellCept® in renal transplant recipients.
    Lawen, J
    Davies, E
    Mourad, G
    Oppenheimer, F
    Gonzalez-Molina, M
    Bourbigot, B
    Durand, D
    Mulloy, L
    Wilkinson, A
    Girault, D
    [J]. TRANSPLANTATION, 2000, 69 (08) : S260 - S260
  • [27] Protocol biopsy findings in HIV positive renal transplant recipients.
    Fyfe, BS
    Veith, LC
    Heifets, MS
    Kumar, AM
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 206 - 206
  • [28] Clinical Outcomes of Kidney Transplant Recipients by Steroid Early Withdraw Protocol with Basiliximab Induction
    Takada, Y.
    Hotta, K.
    Iwami, D.
    Higuchi, H.
    Hirose, T.
    Sasaki, H.
    Shinohara, N.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 576 - 576
  • [29] Pharmacoeconomic evaluation of Simulect prophylaxis in renal transplant recipients
    Walters, SJ
    Whitfield, M
    Akehurst, RL
    Chilcott, JB
    [J]. TRANSPLANTATION PROCEEDINGS, 2001, 33 (7-8) : 3187 - 3191
  • [30] Use of Thymoglobulin in Low Dose Schemes as Induction Therapy in High Risk Kidney Transplant Recipients.
    Perez-Vega, D.
    Rojas-Campos, E.
    Salvador, M. -C.
    Evangelista-Carrillo, L.
    Molina-Ruiz, F.
    Gomez-Navarro, B.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 318 - 318
12345